Black Rock Inc. Champions Oncology, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Champions Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 115,683 shares of CSBR stock, worth $598,081. This represents 0.0% of its overall portfolio holdings.

Number of Shares

115,683

Previous 116,097 0.36%

Holding current value

$598,081

Previous $652,000 13.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$4.9 - $6.91 $2,028 - $2,860	-414 Reduced 0.36%	115,683 $566,000
Q4 2023 Feb 13, 2024	SELL	$4.56 - $6.59 $911 - $1,318	-200 Reduced 0.17%	116,097 $652,000
Q3 2023 Nov 13, 2023	SELL	$5.2 - $7.32 $4,378 - $6,163	-842 Reduced 0.72%	116,297 $722,000
Q2 2023 Aug 11, 2023	BUY	$4.11 - $6.81 $5,310 - $8,798	1,292 Added 1.12%	117,139 $747,000
Q1 2023 May 12, 2023	SELL	$4.0 - $4.67 $24,844 - $29,005	-6,211 Reduced 5.09%	115,847 $465,000

Q4 2022 Feb 13, 2023	SELL	$3.75 - $7.1 $292 - $553	-78 Reduced 0.06%	122,058 $550,000
Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.47 $8,817 - $11,581	-1,223 Reduced 0.99%	122,136 $916,000
Q2 2022 Aug 12, 2022	BUY	$6.81 - $8.31 $3,820 - $4,661	561 Added 0.46%	123,359 $988,000
Q1 2022 May 12, 2022	SELL	$7.26 - $8.53 $4,704 - $5,527	-648 Reduced 0.52%	122,798 $999,000
Q4 2021 Feb 10, 2022	BUY	$7.76 - $10.23 $8,132 - $10,721	1,048 Added 0.86%	123,446 $1.03 Million
Q3 2021 Nov 09, 2021	BUY	$9.11 - $10.96 $140,075 - $168,520	15,376 Added 14.37%	122,398 $1.25 Million
Q2 2021 Aug 11, 2021	BUY	$8.45 - $11.72 $904,335 - $1.25 Million	107,022 New	107,022 $1.1 Million

Others Institutions Holding CSBR

# of Institutions

Shares Held

5.67M

Call Options Held

2.6K

Put Options Held

9.2K

View Full List

About CHAMPIONS ONCOLOGY, INC.

Ticker CSBR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,522,400
Market Cap $69.9M
Description
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Techn...

More about CSBR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account